Search Videos and More

Showing 25 - 36 of 183 results

Previous| 1... 2 | 3 | 4 ...16 |Next


Dana-Farber Cancer Institute Faculty Among World’s Most Highly Cited Researchers News

Dana-Farber Cancer Institute Faculty Among World’s Most Highly Cited Researchers

Dana-Farber Cancer Institute is proud to announce that 33 of its researchers have been named to the Highly Cited Researchers list of 2022 released today by the Institute for Scientific Information at Clarivate.
Study Shows That Immune System Holds Clues to Patients With High-Risk Smoldering Myeloma Likely to Benefit From Treatment News

Study Shows That Immune System Holds Clues to Patients With High-Risk Smoldering Myeloma Likely to Benefit From Treatment

In a new study, investigators at Dana-Farber Cancer Institute demonstrate that changes in immune system cells can indicate which patients with high-risk "smoldering" myeloma are likely to progress to myeloma and which will benefit the most from treatment.
Treatment Guidelines: Trastuzumab Deruxtecan (T-DXd) for Metastatic, HER2-low Breast Cancer Document

Treatment Guidelines: Trastuzumab Deruxtecan (T-DXd) for Metastatic, HER2-low Breast Cancer

The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on July 1 and July 8, 2022 to discuss recommendations for the use of trastuzumab deruxtecan (T-DXd) in patients with metastatic, HER2-low breast cancer.
Research Updates - Metastatic Breast Cancer Symposium

Research Updates - Metastatic Breast Cancer

In the following videos, faculty from Dana-Farber Cancer Institute review research updates from the 2022-2023 EMBRACE Metastatic Breast Cancer Patient Forum Series.
Three of the World’s Top Research Institutions Join Forces to Drive Progress Against Pediatric Cancer News

Three of the World’s Top Research Institutions Join Forces to Drive Progress Against Pediatric Cancer

Large-scale collaboration will leverage each institution’s expertise and infrastructure to advance understanding of the biological basis of pediatric cancers, identify new vulnerabilities of these diseases and accelerate cures globally.
Computer Platform Helps Match Patients With Cancer to Trials of Targeted Therapy News

Computer Platform Helps Match Patients With Cancer to Trials of Targeted Therapy

MatchMiner shortens time to identify appropriate precision medicine trials for individual patients
Study Finds Individuals With Inflammatory Breast Cancer at Higher Risk of Cancer Spread to the Brain News

Study Finds Individuals With Inflammatory Breast Cancer at Higher Risk of Cancer Spread to the Brain

New research from Dana-Farber Cancer Institute indicates that among individuals with breast cancer, those with a rare subtype called inflammatory breast cancer face a higher risk that their cancer will spread, or metastasize, to the brain.
Dana-Farber’s Kornelia Polyak Elected to the National Academy of Medicine News

Dana-Farber’s Kornelia Polyak Elected to the National Academy of Medicine

Kornelia Polyak, M.D., Ph.D., professor of medicine, medical oncology, Dana-Farber Cancer Institute has been elected to the prestigious National Academy of Medicine.
Kornelia Polyak Wins Prestigious American Cancer Society Award News

Kornelia Polyak Wins Prestigious American Cancer Society Award

Kornelia Polyak, MD, PhD, a breast cancer researcher at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School is the recipient of the American Cancer Society’s prestigious Research Professor Award.
Treatment Guidelines: Adjuvant Olaparib for BRCA1/2 Variant Carriers Document

Treatment Guidelines: Adjuvant Olaparib for BRCA1/2 Variant Carriers

The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on May 6, May 20, June 1, and August 5, 2022 to discuss recommendations for the use of adjuvant olaparib for high-risk, breast cancer in BRCA1/2 carriers.
News

Symposium Highlights 75 Years of Dana-Farber Science

Treatment Guidelines: Reflex Testing of OncotypeDX for Early Stage Breast Cancer Document

Treatment Guidelines: Reflex Testing of OncotypeDX for Early Stage Breast Cancer

The Breast Oncology Center held multidisciplinary meetings to discuss recommendations for updated criteria for reflex testing of OncotypeDX in patients with resected, hormone receptor positive, HER-2 negative, early breast cancer.

Showing 25 - 36 of 183 results

Previous| 1... 2 | 3 | 4 ...16 |Next